Skip to main content
Premium Trial:

Request an Annual Quote

Helix Coronavirus Test FDA EUA Reissued to Include Specimen Self-Collection

NEW YORK — The US Food and Drug Administration has reissued an Emergency Use Authorization for Helix's PCR-based SARS-CoV-2 test, allowing its use with self-collected specimens and in asymptomatic individuals for screening or population-based testing, the company said on Monday.

The Helix COVID-19 Test is designed to detect the SARS-CoV-2 nucleocapsid, ORF1ab, and spike protein genes. It first received EUA from the FDA in July for use with upper respiratory specimens collected by healthcare providers from individuals suspected of SARS-CoV-2 infection. 

San Mateo, California-based Helix said that this EUA has now been reissued, expanding it to include unsupervised specimen collection in people with or without COVID-19 symptoms.

"Being able to broadly test individuals irrespective of symptoms is critical to ensure we're able to prevent and mitigate outbreaks and identify people as early as possible in the course of infection," Helix Cofounder and President James Lu said in a statement. "Further, reducing the barriers to testing enables us to reach some of the most vulnerable and underserved populations in the US."

In August, Helix received EUA from the FDA for a next-generation sequencing-based SARS-CoV-2 test.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more